PIONEERING RESPIRATORY CARE
The InhalPlus Innovation
Solving the Core Limitation of Inhalation Therapy
Our patented bypass technology addresses the fundamental limitation of conventional inhalation systems by preventing ventilation circuit dilution and enabling effective, non-invasive delivery of highly concentrated aerosols under respiratory support.
Key features:
-
Targeted drug delivery:
Medication reaches the lungs without dilution in the breathing circuit.
-
Higher efficiency:
Significant increase in drug delivery, backed by lab trials.
-
Non-invasive application:
No intravenous administration.
-
Maintains CPAP/ventilation continuity:
Avoids disconnections and pressure fluctuations.
Prof. Egbert Herting
„This technology has the potential to fundamentally improve the treatment of even very small patients.“
USE CASES
Our technology is designed to address multiple
high-value clinical use cases
1
Preterm infants with BPD
Why change is needed
Immature lungs expose preterm infants to a high risk of chronic respiratory disease, while current therapies remain limited by invasiveness or insufficient effectiveness under respiratory support.
Market potential
The lack of a clinically effective inhalation therapy under respiratory support has left neonatal intensive care with a significant unmet need in the treatment of BPD, defining a focused and economically relevant market.
Our solution
InhalPlus is designed to enable early, preventive aerosol therapy in preterm infants by ensuring that inhaled medication reaches the lungs in effective concentrations despite respiratory support, reducing reliance on invasive systemic treatments.
2
COPD
Why change is needed
During acute COPD exacerbations, adult patients require rapid delivery of high drug concentrations to the lungs while on respiratory support, a need current inhalation systems cannot reliably meet due to dilution in the ventilation circuit.
Our solution
InhalPlus is designed to enable rapid, high-concentration aerosol delivery to the lungs under respiratory support by preventing ventilation circuit dilution, addressing a critical limitation in the treatment of acute COPD exacerbations.
3
Surfactant
Why change is needed
Surfactant therapy in preterm infants relies predominantly on invasive administration, as conventional inhalation approaches fail to deliver sufficient drug concentrations to the lungs under respiratory support.
Our solution
InhalPlus is designed to enable non-invasive surfactant delivery by achieving effective lung deposition under respiratory support, with the potential to replace the need for invasive administration in vulnerable preterm infants.
TEAM
InhalPlus unites a core team with deep expertise in inhalation technology, medical devices, product development, financing, and regulatory affairs.
Dr. Felix Carl Wiegandt
Representation & Strategy
With more than 12 years of experience in inhalation technology and MedTech, his doctoral research laid the scientific foundation of InhalPlus, complemented by leadership of multiple translational development projects at Fraunhofer ITEM.
Dr. Gerhard Pohlmann
Scientific Lead
With over 40 years of experience in aerosol science and medical technology, including authorship of 23 patent families, he ensures the scientific depth, rigor and translational credibility of the InhalPlus technology.
Prof. Dr. Dirk Schäfer
Financial Lead
With more than 30 years of experience in financial leadership as a managing director, board member, academic lecturer and startup investor, he provides strategic financial guidance and long-term economic oversight.
Dr. Ute Urban
Regulatory Lead
With approximately 25 years of experience in research and industry, and deep expertise in MDR and MDD pathways up to class III devices, she leads the regulatory strategy and compliance of InhalPlus.
Fabian Müller
Design & Engineering Lead
With over 10 years of experience in inhalation system development and applied medical device engineering, he translates clinical and scientific requirements into robust, practice-ready product designs.
“I can attest their extraordinary motivation and scientific excellence”
(Prof. Clive Page, King’s College London)
NEWS
Latest News and Updates
Updates from conferences, industry events and project milestones as we share progress, recognition and perspectives from our journey in respiratory care innovation.
CONTACT
Interested in partnering with us?
We invite investors and clinical partners to engage with us in advancing non-invasive inhalation technology toward clinical adoption and long-term impact in respiratory care.
CONTACT
Interested in partnering with us?
We invite investors and clinical partners to engage with us in advancing non-invasive inhalation technology toward clinical adoption and long-term impact in respiratory care.
